Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma

BACKGROUND. Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population. METHODS. Using the Nat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Margalit, Ofer, Mamtani, Ronac, Kopetz, Scott, Yang, Yu‐Xiao, Lawrence, Yaacov R., Abu‐Gazala, Samir, Reiss, Kim A., Golan, Talia, Halpern, Naama, Aderka, Dan, Giantonio, Bruce, Shacham‐Shmueli, Einat, Boursi, Ben
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693732/
https://ncbi.nlm.nih.gov/pubmed/30696723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0333
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados